Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inflammatory Arthritis Clear all
Active, not recruiting Phase 3 Interventional

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214
View directory record Official record
Conditions
Sjogren Syndrome
Interventions
VAY736, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
23
States / cities
Fullerton, California • La Palma, California • Brandon, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 18, 2026, 2:40 PM EDT
Completed No phase listed Observational Results available

Start Time Optimization of Biologics in Polyarticular JIA

NCT02593006
View directory record Official record
Conditions
Polyarticular Juvenile Rheumatoid Arthritis, Arthritis, Juvenile Idiopathic
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
2 Years to 18 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
52
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 18, 2026, 2:40 PM EDT
Not listed No phase listed Observational

Quantitative Assessment of Walking (Squawk) With the Canary canturioTM te (CTE) Tibial Extension

NCT05693818
View directory record Official record
Conditions
Arthritis Knee
Interventions
Clinical Limping Evalution
Other
Lead sponsor
Canary Medical
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 18, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Investigation of AVACEN Thermal Exchange System for Fibromyalgia Pain

NCT01619579
View directory record Official record
Conditions
Fibromyalgia
Interventions
AVACEN Thermal Exchange System
Device
Lead sponsor
Avacen, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

NCT02889796
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
48
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 18, 2026, 2:40 PM EDT
Completed Phase 1 Interventional

Intra-articular Transplantation of Autologous Adipose Derived Stromal Vascular Faction (SVF) for Treatment of Osteoarthritis of the Knee

NCT03940950
View directory record Official record
Conditions
Osteo Arthritis Knee, Degenerative Joint Disease of Knee
Interventions
Autologous Adipose-Derived SVF (Stromal Vascular Fraction), Placebo
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 18, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

NCT01645280
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 18, 2026, 2:40 PM EDT
Completed Not applicable Interventional Results available

Development of a Mind Body Program for Obese Knee Osteoarthritis Patients With Comorbid Depression

NCT04334278
View directory record Official record
Conditions
Knee Osteoarthritis, Obesity, Depression
Interventions
GetHealthy-OA, Health Enhancement Program
Behavioral
Lead sponsor
University of Kentucky
Other
Eligibility
45 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 18, 2026, 2:40 PM EDT
Completed No phase listed Observational Results available

ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis

NCT04138017
View directory record Official record
Conditions
Ankle Deformity, Ankle Arthritis
Interventions
ViviGen
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Sep 18, 2026, 2:40 PM EDT
Terminated Phase 4 Interventional Results available

NSAIDs vs. Coxibs in the Presence of Aspirin

NCT03699293
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Diseases
Interventions
celecoxib 200mg capsule, naproxen sodium 550mg tablet, Aspirin 81mg tablet
Drug
Lead sponsor
Platelet and Thrombosis Research, LLC
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 18, 2026, 2:40 PM EDT
Terminated Phase 4 Interventional Results available

Trilogy AB Acetabular Hip System Post Approval Study

NCT00715026
View directory record Official record
Conditions
Osteoarthritis, Avascular Necrosis, Congenital Hip Dysplasia, Traumatic Arthritis
Interventions
Trilogy AB Acetabular Hip Implant System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Sep 18, 2026, 2:40 PM EDT
Recruiting Phase 3 Interventional

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

NCT06654882
View directory record Official record
Conditions
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Interventions
TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab, Tofacitinib
Drug
Lead sponsor
Duke University
Other
Eligibility
2 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 18, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

NCT00938587
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PF-04171327 10 mg, Prednisone Placebo, PF-04171327 25 mg, Prednisone 5 mg, Placebo for PF-04171327, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Anniston, Alabama • Daytona Beach, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 18, 2026, 2:40 PM EDT
Completed Not applicable Interventional Results available

Living Well With Rheumatoid Arthritis

NCT00869349
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
IFS, Education
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 81 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 18, 2026, 2:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis

NCT00001885
View directory record Official record
Conditions
Healthy, Pulmonary Fibrosis, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 18, 2026, 2:40 PM EDT
Active, not recruiting No phase listed Observational

Zimmer Continuum Metal on Polyethylene (MoP) PostMarket Clinical Followup (PMCF) Study

NCT01307384
View directory record Official record
Conditions
Avascular Necrosis, Osteoarthritis, Inflammatory Arthritis, Post-traumatic Arthritis, Rheumatoid Arthritis
Interventions
Continuum Metal on Polyethylene Acetabular System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
2
States / cities
Fremont, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 18, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device

NCT01618955
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
VIBEX MTX
Device
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Sep 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

NCT04936308
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
50
States / cities
Mountain Brook, Alabama • Avondale, Arizona • Flagstaff, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

NCT03769168
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
Interventions
Secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Boise, Idaho • Cincinnati, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 18, 2026, 2:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

NCT01741493
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ABT-494, Placebo, Tofacitinib
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Miami, Florida • Cincinnati, Ohio • Duncansville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 18, 2026, 2:40 PM EDT
Completed No phase listed Observational

A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis

NCT01209585
View directory record Official record
Conditions
Arthritis
Interventions
Blood samples, Synovial fluid aspiration, Synovial tissue sample
Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Frederick, Maryland • Wyomissing, Pennsylvania • Jackson, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Sep 18, 2026, 2:40 PM EDT
Terminated Not applicable Interventional

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

NCT04313725
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 18, 2026, 2:40 PM EDT
Completed Not applicable Interventional Results available

Investigation of Sacroiliac Fusion Treatment (INSITE)

NCT01681004
View directory record Official record
Conditions
Degenerative Sacroiliitis, Sacroiliac Joint Disruption
Interventions
iFuse Implant System, Non-surgical management
Device · Other
Lead sponsor
SI-BONE, Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
19
States / cities
La Jolla, California • Newport Beach, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

NCT05586958
View directory record Official record
Conditions
Gout, Hyperuricemia, Gout Flare, Tophi
Interventions
Tigulixostat, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 85 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
36
States / cities
Birmingham, Alabama • Covina, California • Clearwater, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 18, 2026, 2:40 PM EDT